Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Autolus Therapeutics (AUTL)

Autolus Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AUTL
DateTimeSourceHeadlineSymbolCompany
17/05/202413:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
17/05/202412:00GlobeNewswire Inc.Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
14/05/202415:00GlobeNewswire Inc.Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202414:33Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202412:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202412:00GlobeNewswire Inc.Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallNASDAQ:AUTLAutolus Therapeutics PLC
24/04/202415:00GlobeNewswire Inc.Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
23/04/202412:00GlobeNewswire Inc.Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/04/202412:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALLNASDAQ:AUTLAutolus Therapeutics PLC
01/04/202412:00GlobeNewswire Inc.Autolus Therapeutics Announces Changes to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
14/03/202411:00GlobeNewswire Inc.Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
12/03/202411:00GlobeNewswire Inc.Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteNASDAQ:AUTLAutolus Therapeutics PLC
11/03/202411:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Blood Cancer JournalNASDAQ:AUTLAutolus Therapeutics PLC
29/02/202412:00GlobeNewswire Inc.Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
23/02/202422:28Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AUTLAutolus Therapeutics PLC
22/02/202412:00GlobeNewswire Inc.Autolus Therapeutics announces publication in Nature Communications NASDAQ:AUTLAutolus Therapeutics PLC
21/02/202422:01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AUTLAutolus Therapeutics PLC
14/02/202413:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
09/02/202422:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202412:00GlobeNewswire Inc.Autolus Announces Pricing of Underwritten OfferingNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202411:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202410:45GlobeNewswire Inc.BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202403:00Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AUTLAutolus Therapeutics PLC
31/01/202421:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
26/01/202418:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
23/01/202412:00GlobeNewswire Inc.Autolus Therapeutics announces publication in ACS Chemical BiologyNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202412:54Dow Jones NewsAutolus Therapeutics Gets BLA Acceptance for Obecabtagene AutoleucelNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202412:00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)NASDAQ:AUTLAutolus Therapeutics PLC
10/01/202420:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AUTL

Your Recent History

Delayed Upgrade Clock